Sunil Agarwal

Dr. Agarwal is Chief Development Officer and Head Portfolio Strategy at Sana Biotechnology. Previously, Dr. Agarwal was President of Research and Development at Juno Therapeutics, where he was responsible for the company’s drug development pipeline and the integration of translational insights into ongoing programs. Prior to his role at Juno Therapeutics, Dr. Agarwal was Chief Medical Officer and Executive Vice President at Ultragenyx where he was responsible for the company’s clinical development. Dr. Agarwal also served in various leadership capacities at Genentech for 11 years, he held the position of Senior Vice President and Global Head of Clinical Development for OMNI (Ophthalmology, Metabolism, Neuroscience, Immunology, and Infectious Diseases). He was responsible for the development of programs in these areas from proof of concept through Phase IV. Dr. Agarwal received his bachelor of science in Neuro-Biology at Cornell University and earned his medical degree from Tufts University School of Medicine. He completed his residency at Children’s National Medical Center, Washington, D.C., and subsequently joined the faculty at George Washington University School of Medicine.